Elyxium Wealth LLC Has $7.30 Million Position in Eli Lilly and Company $LLY

Key Points

• Elyxium Wealth increased its Eli Lilly position by 268.5% in the second quarter, holding 6,087 shares valued at approximately $7.3 million. Institutional investors and hedge funds collectively own 82.53% of LLY.
• Eli Lilly reported strong quarterly results, with revenue rising 47.7% year over year to $22.97 billion and EPS of $8.38, well above estimates. Analysts maintain a “Moderate Buy” consensus, with an average price target of $1,292.18.
• Executives sold shares under pre-arranged Rule 10b5-1 plans, while the company declared a quarterly dividend of $1.73 per share, equivalent to an annualized yield of about 0.6%.

Elyxium Wealth LLC raised its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 268.5% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 6,087 shares of the company's stock after purchasing an additional 4,435 shares during the period. Elyxium Wealth LLC's holdings in Eli Lilly and Company were worth $7,302,000 as of its most recent filing with the SEC.

Other hedge funds also recently bought and sold shares of the company. Sage Rhino Capital LLC grew its holdings in shares of Eli Lilly and Company by 0.9% in the 2nd quarter. Sage Rhino Capital LLC now owns 2,014 shares of the company's stock valued at $2,416,000 after buying an additional 17 shares during the period. Total Investment Management Inc. raised its stake in Eli Lilly and Company by 4.5% during the 2nd quarter. Total Investment Management Inc. now owns 256 shares of the company's stock worth $294,000 after buying an additional 11 shares during the period. Keynote Financial Services LLC raised its stake in Eli Lilly and Company by 6.6% during the 2nd quarter. Keynote Financial Services LLC now owns 2,030 shares of the company's stock worth $2,435,000 after buying an additional 126 shares during the period. ProVise Management Group LLC lifted its holdings in Eli Lilly and Company by 10.8% during the second quarter. ProVise Management Group LLC now owns 1,561 shares of the company's stock worth $1,872,000 after acquiring an additional 152 shares in the last quarter. Finally, Mokosak Advisory Group LLC bought a new position in Eli Lilly and Company during the second quarter worth about $256,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

LLY has been the subject of several recent analyst reports. Morgan Stanley restated an "overweight" rating and issued a $1,419.00 price target on shares of Eli Lilly and Company in a report on Thursday, August 6th. JPMorgan Chase & Co. lifted their price objective on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the company an "overweight" rating in a report on Tuesday, July 7th. Rothschild & Co Redburn boosted their price objective on Eli Lilly and Company from $880.00 to $900.00 in a research report on Thursday, May 7th. Guggenheim increased their target price on Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the stock a "buy" rating in a research note on Monday, July 13th. Finally, UBS Group set a $1,376.00 target price on Eli Lilly and Company in a research note on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Eli Lilly and Company has an average rating of "Moderate Buy" and an average price target of $1,292.18.

Insider Activity at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 2,000 shares of the firm's stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the transaction, the chief accounting officer directly owned 1,526 shares of the company's stock, valued at $1,808,325.26. This trade represents a 56.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares in the company, valued at $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.14% of the company's stock.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The U.K. regulator approved Lilly’s once-daily oral weight-loss pill, Foundayo (orforglipron), giving the company a potentially important first-mover advantage for an obesity pill in Europe. The approval expands Lilly’s addressable market beyond injectable treatments such as Mounjaro and Zepbound. Eli Lilly Just Scored Europe's First Weight Loss Pill Approval
• Positive Sentiment: Lilly is expanding its obesity pipeline with a new Phase 1 macupatide study in Japan. Although early-stage, the trial reinforces the company’s efforts to develop additional weight-management therapies and support long-term growth. Lilly Expands Obesity Pipeline With Fresh Macupatide Trial in Japan
• Positive Sentiment: Recent earnings showed continued operating momentum: quarterly revenue rose about 48% year over year to roughly $23 billion, while adjusted EPS beat expectations. Growth was led by Mounjaro, Zepbound and other key medicines, and management raised full-year 2026 guidance. Foundayo also generated an initial $98 million in quarterly sales. 5 Revealing Analyst Questions From Eli Lilly’s Q2 Earnings Call
• Neutral Sentiment: Analysts continue to view LLY as a fundamental leader, with reported price targets generally above the current trading level. However, the stock is approaching a technical buy point after a large earnings-driven advance, making valuation and chart resistance important near-term considerations. Eli Lilly Stock Nears Buy Point After Earnings-Fueled Gains
• Negative Sentiment: Insider-selling headlines may be adding pressure: executives have sold shares in recent months, including a reported 2,000-share sale by CFO and Chief Accounting Officer Donald Zakrowski. Lilly also trades at a demanding earnings multiple, leaving the stock sensitive to profit-taking or any signs of slower obesity-drug growth. Donald Zakrowski Sells 2,000 Shares of Eli Lilly Stock

Eli Lilly and Company Price Performance

LLY stock opened at $1,182.24 on Friday. The stock has a 50-day moving average price of $1,170.82 and a two-hundred day moving average price of $1,052.76. Eli Lilly and Company has a 1 year low of $685.15 and a 1 year high of $1,249.45. The stock has a market cap of $1.11 trillion, a PE ratio of 39.67, a price-to-earnings-growth ratio of 1.39 and a beta of 0.51. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating analysts' consensus estimates of $6.40 by $1.98. The company had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The company's quarterly revenue was up 47.7% compared to the same quarter last year. During the same period in the previous year, the company posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities analysts forecast that Eli Lilly and Company will post 36.35 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company's dividend payout ratio (DPR) is currently 23.22%.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source